68Ga-PSMA and 68Ga-FAPI-04 PET/CT Findings With 18F-FDG PET/CT in a Patient With Recurrent Prostate Cancer-Reference-Cited by-同舟云学术

68Ga-PSMA and 68Ga-FAPI-04 PET/CT Findings With 18F-FDG PET/CT in a Patient With Recurrent Prostate Cancer

Published:2023-01-10 Issue:3 Volume:48 Page:e135-e137
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

Tatar Gamze¹,Ergül Nurhan²,Baloğlu Mehmet Can²,Arslan Esra²,Çermik Tevfik Fikret²

Affiliation:

1. University of Health Sciences, Department of Nuclear Medicine, Istanbul Bagcilar Training and Research Hospital

2. University of Health Sciences, Clinic of Nuclear Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey.

Abstract

Abstract A 79-year-old man with prostate cancer was evaluated with 68Ga–prostate-specific membrane antigen (PSMA), 68Ga-FAPI-04, and 18F-FDG PET/CT scans since a rise in prostate-specific antigen was seen at last control while receiving chemotherapy. Abnormal FDG uptakes were observed in the tumoral areas of the left half of the prostate and walls of the bladder, although PSMA and FAPI activity were absent or lower in the relevant tumoral areas. Restaging 68Ga-PSMA and 18F-FDG PET/CT scans were obtained on the patient whose progression continued after transurethral tumor resection. Herein, we present a case proving intraindividual tumor heterogeneity in prostate cancer underwent PET/CT imaging with 3 different radiopharmaceuticals.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference10 articles.

1. Diagnostic value of 18F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative 68Ga-PSMA PET/CT;Eur J Nucl Med Mol Imaging,2021

2. Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review;Adv Urol,2021

3. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging;Ann Nucl Med,2022

4. A tumor-imaging method targeting cancer-associated fibroblasts;J Nucl Med,2018

5. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer;J Nucl Med,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers;Journal of Nuclear Medicine;2024-04-18

2. Contribution of 68Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging;Clinical Nuclear Medicine;2024-01-25